Aurobindo Pharma Ltd
Ticker: AUROPHARMA
Decent
70/100
☆ Add to Watchlist
Investing Reference
Price
1109.00
Market Cap
64410.90
Debt/Equity
0.2530
ROE %
11.155
PB
1.9728
Promoter %
51.816
Pledge %
9.067
1Y Rev Growth %
9.426
5Y Rev Growth %
6.789
NP Margin %
10.777
NP Margin 5Y Avg %
11.808
Trading Reference
1M Return %
3.458
6M Return %
-2.265
1Y Return %
-25.070
% Away 52W High
35.212
% Away 52W Low
9.802
Daily Volume
543500
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 17/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Aurobindo Pharma Ltd is likely to face resistance around the ₹600 level, with support at ₹500. If the stock breaks above ₹600, it could see an upside of approximately 15%, while a drop below ₹500 could lead to a downside of around 10%.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
F
Fertilisers And Chemicals Travancore Ltd
Fertilisers And Chemicals Travancore Ltd shows potential but faces several challenges that could impact its growth and stability.
View details
M
Motilal Oswal Financial Services Ltd
Motilal Oswal Financial Services Ltd shows potential for growth, but faces challenges in profitability and market competition.
View details
B
Berger Paints India Ltd
Berger Paints India Ltd shows decent potential with a strong brand and growth prospects, but faces challenges in valuation and market sentiment.
View details
T
Tube Investments of India Ltd
Tube Investments of India Ltd shows decent potential with consistent growth and profitability metrics, but faces some risks in execution and valuation relative to peers.
View details
M
MRF Ltd
MRF Ltd shows decent fundamentals and growth potential, but faces challenges in profitability and valuation metrics.
View details
S
Schaeffler India Ltd
Schaeffler India Ltd shows a decent investment opportunity with solid growth potential, but investors should be cautious of profitability inconsistencies and valuation concerns.
View details
J
Jindal Stainless Ltd
Jindal Stainless Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
G
Godrej Properties Ltd
Godrej Properties Ltd shows potential for growth in a competitive sector, but faces challenges in valuation and execution risks.
View details
G
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
C
Coforge Ltd
Coforge Ltd presents a decent investment opportunity with solid growth prospects, though valuation and liquidity concerns should be monitored.
View details
L
L&T Finance Ltd
L&T Finance Ltd shows potential in a growing sector, but faces challenges in growth consistency and market sentiment.
View details
B
Bharat Forge Ltd
Bharat Forge Ltd shows potential for growth and profitability, but investors should be cautious of valuation and execution risks.
View details
O
Oberoi Realty Ltd
Oberoi Realty Ltd shows potential for growth with a solid business model, but valuation concerns and execution risks warrant caution.
View details
I
Indian Railway Catering and Tourism Corporation Ltd
The stock has a decent outlook with growth potential, but faces several risks that could impact performance.
View details
I
Indusind Bank Ltd
Indusind Bank shows potential for growth but faces challenges in profitability and market competition.
View details
S
Supreme Industries Ltd
Supreme Industries Ltd shows decent potential for growth with a strong market position, but investors should be cautious of valuation and execution risks.
View details
Business Overview
Aurobindo Pharma Ltd is a leading Indian pharmaceutical company dedicated to manufacturing high-quality generic medicines and active pharmaceutical ingredients. Catering to healthcare providers and patients globally, the company plays a crucial role in making essential medications accessible. Aurobindo's commitment to innovation and compliance with international standards ensures trust and reliability in its products. With a strong focus on research and development, it continually expands its portfolio to meet diverse healthcare needs.
- Leading manufacturer of generic medicines
- Strong global presence in pharmaceuticals
- Commitment to quality and compliance
- Innovative research and development
- Focus on accessibility of essential medications
Investment Thesis
Aurobindo Pharma Ltd stands out due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company favorably for long-term growth, making it a compelling investment opportunity for retail investors.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services segment poised for substantial growth, diversifying revenue streams.
- Attractive valuation metrics compared to industry peers present a buying opportunity.
- Robust product pipeline and global presence support sustainable earnings growth.
- Commitment to R&D ensures competitive edge in the pharmaceutical sector.
Opportunity vs Risk
Opportunities
- Strong product pipeline
- Expanding global market presence
- Potential for new drug approvals
- Cost-effective manufacturing processes
- Strategic acquisitions planned
Risks ⚠️
- Regulatory challenges in markets
- Pricing pressure on generics
- Currency fluctuation impacts
- Competition from local players
- Supply chain disruptions
Peer Perspective
Aurobindo Pharma Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin pressures. A sustained improvement in operational efficiency could trigger a rerating in its valuation.
Future Outlook
Aurobindo Pharma Ltd is well-positioned for growth, driven by its robust pipeline and expanding global presence. Successful execution of its strategic initiatives and effective cost control will be crucial for maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Aurobindo Pharma do?A: Aurobindo Pharma is a leading pharmaceutical company specializing in generic medicines and active pharmaceutical ingredients.
- Q: Is Aurobindo Pharma a good investment?A: Investment decisions should be based on personal financial goals and thorough research. Consult a financial advisor.
- Q: What are the risks of investing in Aurobindo Pharma?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy Aurobindo Pharma shares?A: You can buy shares through a stockbroker or an online trading platform.
- Q: What factors affect Aurobindo Pharma's stock price?A: Factors include company performance, industry trends, regulatory news, and overall market conditions.
📊 Stock Investment Checklist (100 Points)
Aurobindo Pharma Ltd • Updated: 2025-09-17 06:21:52
-
10BusinessHighPharmaceutical sector is essential but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth but profit margins under pressure.
-
10ProfitabilityHighROE and ROCE are decent but OCF is fluctuating.
-
10ValuationHighValuation metrics are in line with peers but not compelling.
-
8BalanceHighModerate debt levels but liquidity is a concern.
-
7GovernanceHighPromoter holding is stable, but some pledging exists.
-
5DriversGoodGrowth drivers exist but execution risks are significant.
-
3TechnicalsLowWeak momentum and liquidity issues observed.
Final Score & Verdict
Score 70 / 100
• Decent
Aurobindo Pharma shows potential for growth but faces significant challenges that may impact its performance.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100